Vai al contenuto principale
xMedica

NCT06605404ClinicalTrials.gov

Pan-tumor MRD Study

Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers

In reclutamentoAccetta partecipanti ora, secondo la scheda del registro.
Contatta questo studio

In breve

The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to…

Osservazionale1350 partecipanti ricercati47 centri1 paese

Categorie

Registrato in 1 registro

Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.

Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.

Ti interessa questo studio?

Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2024-09-20; recorded start 2025-01-08
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Whether participants are randomly assigned is not stated in the registry recordNo allocation method is recorded
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Not stated: Whether the study is blinded is not stated in the registry recordNo masking information is recorded
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Not stated: No other studies from this sponsor are in this databaseCounted from the lead sponsor named in the record (Paradigm Health)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 7 conditions.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Masking not stated in the record

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre5/8

    Multi-centre: 2 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study: 1,350 participants (target), run at 47 sites.

How this score is built
  • Enrolment31/40

    1,350 participants (target)

  • Site count4/25

    2 sites

  • Country count0/15

    Single country

  • Planned duration10/10

    Planned over about 88 months

  • Sponsor scale0/10

    Paradigm Health has led 1 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Sintesi

The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back. Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.

Patologie

  • Muscle Invasive Bladder Urothelial Carcinoma
  • Esophageal Cancer
  • Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
  • Melanoma (Skin Cancer)
  • NSCLC (Non-small Cell Lung Cancer)
  • Pancreatic (Exocrine Only)
  • Mix of Solid Tumors (MOST)

Idoneità

Idoneità
SessoTutti
Età18 Years – Nessun massimo
Volontari saniNo
Metodo di campionamentoNON_PROBABILITY_SAMPLE

Popolazione dello studio

Study participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors

Idoneità come riportata nel registro

Eligibility Criteria: 1. Age 18 years or older. 2. Confirmed histological or cytological diagnosis of a malignant solid tumor that is either specified in one of the pre-defined tumor cohorts or meets the enrollment criteria for the Mix of Solid Tumors (MOST) cohort (Table 1). 3. Eligible for curative intent therapy, with surgical resection of cancer planned. a. If surgical resection has occurred, enrollment should occur within 3 months of surgical resection and before initiation of adjuvant therapy. 4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2. 5. No systemic therapy for current cancer diagnosis administered before enrollment. 6. Willing and able to comply with required study procedures, including blood sample collection and primary tumor tissue submission from diagnostic biopsy or surgical excision. 7. Has completed all therapy (including endocrine therapy) 3 or more years ago for any previous invasive solid organ malignancy (with exception of nonmelanoma skin cancers) or hematologic malignancy. Individuals with a prior history of noninvasive (in situ) carcinomas may participate if they have received definitive treatment (no washout period required). 8. No concurrent diagnosis of another invasive cancer, except for nonmelanoma skin cancers. 9. No prior allogeneic hematopoietic stem cell transplant. 10. Able and willing to provide informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for the release of personal health information. Cohort Specific Criteria 11. Muscle-invasive urothelial carcinoma of the bladder and Melanoma Cohorts: Stage II or operable III cancer: 12. Esophageal, Gastric/GEJ, and NSCLC Cohorts: Stage I, II, or operable III cancer. 13. Pancreatic Cohort: Stage I, II or operable III cancer, exocrine only disease. 14. MOST cohort: Stage II or operable stage III solid tumor diagnosis that meets eligibility criteria and is not included in the other cohorts. The following tumor types are excluded: 1. Central nervous system (CNS) malignancies 2. Colorectal cancer 3. Breast cancer 4. Squamous cell skin cancer 5. Basal cell carcinoma 6. Gastrointestinal stromal tumors (GIST) 7. Thyroid cancer 8. Uveal melanoma 9. Low or intermediate grade neuroendocrine tumors ■ Eligible tumor types: High-grade neuroendocrine tumors, including neuroendocrine carcinomas, Merkel cell carcinomas, and small cell lung cancer are permissible 10. Hematologic cancers including multiple myeloma or other plasma cell dyscrasias, Hodgkin\'s lymphoma, non-Hodgkin\'s lymphoma, acute or chronic leukemias including chronic lymphocytic leukemia / small lymphocytic leukemia

Idoneità in frasi semplici

I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.

Disegno dello studio

Disegno dello studio
Tipo di studioOsservazionale
FaseNon indicato nella scheda del registro
AssegnazioneNon indicato nella scheda del registro
Modello di interventoNon indicato nella scheda del registro
Finalità principaleNon indicato nella scheda del registro
MascheramentoNon indicato nella scheda del registro
Arruolamento1350 partecipanti ricercati

Sponsor e collaboratori

  • Paradigm Health Sponsor

Bracci e interventi

  • Muscle Invasive Urothelial Carcinoma of the Bladder (MIBC)

    Muscle Invasive Urothelial Carcinoma of the Bladder (MIBC)

  • Esophageal

    Esophageal cancer

  • Gastric and Gastroesophageal Junction (GEJ)

    Gastric and Gastroesophageal Junction (GEJ)

  • Melanoma

    Melanoma

  • Non-small cell lung (NSCLC)

    Non-small cell lung (NSCLC)

  • Pancreatic (exocrine only)

    Pancreatic (exocrine only)

  • Mix of Solid Tumors (MOST)

    Mix of Solid Tumors (MOST)

Interventi

  • Test diagnostico blood and tissue samples

    routine standard of care

  • Altro blood and tissue samples

    Routine standard of care

Esiti misurati

  1. Esito primario

    Blood and tissue biospecimen registry

    To establish a blood and tissue biospecimen resource in participants with operable solid tumors, with clinical, lab, radiographic, and pathology annotation for the discovery, development, and validation of MRD assays.

    Orizzonte temporale Observation from enrollment to 5.5 years after enrollment

Date

Date
Data di inizio8 gennaio 2025 (effettiva)
Conclusione primaria1 dicembre 2031 (stimata)
Conclusione1 aprile 2032 (stimata)
Prima pubblicazione20 settembre 2024 (effettiva)
Ultimo aggiornamento24 settembre 2026
Risultati pubblicatiNon indicato nella scheda del registro
Stato verificato l'ultima voltasettembre 2026

«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.

Centri

47 centri stanno reclutando

United States

United States
StrutturaCittàStato o regioneStato
Piedmont Cancer InstituteAtlantaGeorgiaIn reclutamento
Guthrie Lourdes Memorial Hospital (GLMH)BinghamtonNew YorkIn reclutamento
Alabama OncologyBirminghamAlabamaIn reclutamento
Mohtaseb Cancer Center and Blood DisordersBullhead CityArizonaIn reclutamento
Gabrail Cancer CenterCantonOhioIn reclutamento
Cancer & Blood Specialists of ArizonaCasa GrandeArizonaIn reclutamento
Carolina Oncology SpecialistsCharlotteNorth CarolinaIn reclutamento
Oncology & Hematology Associates of West BrowardCoral SpringsFloridaIn reclutamento
Baptist Health CorbinCorbinKentuckyIn reclutamento
Pontchartrain Cancer CenterCovingtonLouisianaIn reclutamento
Baptist Health HardinElizabethtownKentuckyIn reclutamento
The Melanoma and Skin Cancer InstituteEnglewoodColoradoIn reclutamento
San Juan Oncology AssociatesFarmingtonNew MexicoIn reclutamento
Los Angeles Cancer Network (LACN)GlendaleCaliforniaIn reclutamento
Southeastern Medical Oncology Center (SMOC)GoldsboroNorth CarolinaIn reclutamento
The Cancer & Hematology Centers (CHC)Grand RapidsMichiganIn reclutamento
Onocology Consultants P.A. (Oncology Consultants [OC Houston])HoustonTexasIn reclutamento
Community Clinical TrialsKingwoodTexasIn reclutamento
Lancaster General Hospital (UPenn)LancasterPennsylvaniaIn reclutamento
Baptist Health LexingtonLexingtonKentuckyIn reclutamento
Cancer Partners of NebraskaLincolnNebraskaIn reclutamento
CARTILittle RockArkansasIn reclutamento
Baptist Health LouisvilleLouisvilleKentuckyIn reclutamento
Taylor Cancer Research CenterMaumeeOhioIn reclutamento
Cancer Care Specialists of Illinois (CCSI)O'FallonIllinoisIn reclutamento
Mid Florida Cancer CentersOrange CityFloridaIn reclutamento
Ventura County Hematology Oncology SpecialistsOxnardCaliforniaIn reclutamento
Oregon Health & Science University (OHSU)PortlandOregonIn reclutamento
Virginia Cancer InstituteRichmondVirginiaIn reclutamento
Mayo ClinicRochesterMinnesotaIn reclutamento
Medical Oncology Associates of San Diego (MOASD)San DiegoCaliforniaIn reclutamento
Medical Oncology Associates of San DiegoSan DiegoCaliforniaIn reclutamento
Guthrie FoundationSayrePennsylvaniaIn reclutamento
New York Cancer & Blood SpecialistsShirleyNew YorkIn reclutamento
Christus Health HighlandsShreveportLouisianaIn reclutamento
Highlands Oncology Group (HOG)SpringdaleArkansasIn reclutamento
Cox HealthSpringfieldMissouriIn reclutamento
Comprehensive Hematology Oncology (CHO)St. PetersburgFloridaIn reclutamento
Stockton Hematology Oncology Med GroupStocktonCaliforniaIn reclutamento
Northwest Medical Specialties (NWMS)TacomaWashingtonIn reclutamento
Christus St. Michael'sTexarkanaTexasIn reclutamento
Cotton O'Neil Cancer Center [Stormont Vail]TopekaKansasIn reclutamento
Oklahoma Cancer Specialists and Research Institute (OCSRI)TulsaOklahomaIn reclutamento
Carle HealthUrbanaIllinoisIn reclutamento
Cancer Center of KansasWichitaKansasIn reclutamento
Regional Medical Oncology CenterWilsonNorth CarolinaIn reclutamento
Cancer Care Associates of York (CCAY)YorkPennsylvaniaIn reclutamento

Documenti dello studio

In questa scheda del registro non sono collegati documenti.

Modifiche nel tempo

  1. 24 settembre 2026

    Centro aggiunto

    45 sites added (47 total)

    247